Identification

Name
Cilazapril
Accession Number
DB01340
Type
Small Molecule
Groups
Approved
Description

Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.

Structure
Thumb
Synonyms
  • Cilazapril
  • Cilazapril anhydrous
  • Cilazaprilum
External IDs
Ro 31-2848
Product Ingredients
IngredientUNIICASInChI Key
Cilazapril monohydrate19KW7PI29F92077-78-6JQRZBPFGBRIWSN-YOTVLOEGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CilazaprilTablet2.5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
CilazaprilTablet1.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
CilazaprilTablet2.5 mgOralSanis Health Inc2010-05-31Not applicableCanada
CilazaprilTablet5 mgOralSanis Health Inc2010-05-312014-08-01Canada
CilazaprilTablet5.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
CilazaprilTablet1 mgOralSanis Health Inc2010-05-31Not applicableCanada
Co CilazaprilTablet2.5 mgOralCobalt Laboratories2007-02-06Not applicableCanada
Co CilazaprilTablet1.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Co CilazaprilTablet5.0 mgOralCobalt Laboratories2007-02-06Not applicableCanada
InhibaceTablet5 mgOralHoffmann La Roche1993-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cilazaprilTablet5 mgOralApotex Corporation2007-02-01Not applicableCanada
Apo-cilazaprilTablet2.5 mgOralApotex Corporation2007-02-01Not applicableCanada
Apo-cilazaprilTablet1 mgOralApotex Corporation2007-02-01Not applicableCanada
Dom-cilazaprilTablet2.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazaprilTablet1.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazaprilTablet5.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Mylan-cilazaprilTablet5.0 mgOralMylan Pharmaceuticals2006-07-21Not applicableCanada
Mylan-cilazaprilTablet2.5 mgOralMylan Pharmaceuticals2006-07-21Not applicableCanada
Mylan-cilazaprilTablet1 mgOralMylan Pharmaceuticals2006-07-21Not applicableCanada
Ntp-cilazaprilTablet1 mgOralTevaNot applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-cilazapril/hctzCilazapril (5 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2006-08-23Not applicableCanada
Inhibace PlusCilazapril (5 mg) + Hydrochlorothiazide (12.5 mg)TabletOralHoffmann La Roche1999-04-01Not applicableCanada
Teva-cilazapril/hctzCilazapril (5 mg) + Hydrochlorothiazide (12.5 mg)TabletOralTeva2009-03-30Not applicableCanada
International/Other Brands
Dynorm (Roche) / Inhibace (Roche) / Inhibestril (Teva) / Vascace (Roche) / Zapril (Mylan) / Zobox (Hemofarm)
Categories
UNII
8Q9454114Q
CAS number
88768-40-5
Weight
Average: 417.4986
Monoisotopic: 417.226371117
Chemical Formula
C22H31N3O5
InChI Key
HHHKFGXWKKUNCY-FHWLQOOXSA-N
InChI
InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
IUPAC Name
(1S,9S)-9-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxo-octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O

Pharmacology

Indication

Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.

Associated Conditions
Pharmacodynamics

Cilazapril inhibits the production angiotensin II. By doing so, it decreases sodium and water reabsorption (via aldosterone) and it decreases vasoconstriction. The combined effect of this is a decrease in vascular resistance, and therefore, blood pressure. The absolute bioavailability of cilazaprilat after oral administration of cilazapril is 57% based on urinary recovery data. (The absolute bioavailability of cilazaprilat after oral administration of cilazaprilat is 19%.) Ingestion of food immediately before the administration of cilazapril reduces the average peak plasma concentration of cilazaprilat by 29%, delays the peak by one hour and reduces the bioavailability of cilazaprilat by 14%. These pharmacokinetic changes have little influence on plasma ACE inhibition.

Mechanism of action

Cilazapril is a pyridazine ACE inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Maximum plasma concentrations of cilazaprilat are reached within two hours after administration of cilazapril.

Volume of distribution
Not Available
Protein binding

Maximum ACE inhibition is greater than 90% after 1 to 5 mg cilazapril. Maximum ACE inhibition is 70 to 80% after 0.5 mg cilazapril. Dose proportionality is observed following the administration of 1 to 5 mg cilazapril. Apparent non-proportionality is observed at 0.5 mg reflective of the binding to ACE. The higher doses of cilazapril are associated with longer duration of maximum ACE inhibition.

Metabolism
Route of elimination

Cilazaprilat is eliminated unchanged by the kidneys. The total urinary recovery of cilazaprilat after intravenous administration of 2.5 mg is 91%.

Half life

Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.

Clearance

Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.

Toxicity

Limited data are available with regard to overdosage in humans. The most likely manifestations are hypotension, which may be severe, hyperkalaemia, hyponatraemia and renal impairment with metabolic acidosis. Treatment should be mainly symptomatic and supportive.

Affected organisms
Not Available
Pathways
PathwayCategory
Cilazapril Metabolism PathwayDrug metabolism
Cilazapril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cilazapril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cilazapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Cilazapril.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Cilazapril.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Cilazapril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Cilazapril.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cilazapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Cilazapril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Cilazapril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Cilazapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Cilazapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cilazapril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cilazapril.Approved
AloxiprinThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Cilazapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Cilazapril.Approved, Withdrawn
AmbrisentanCilazapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Cilazapril.Experimental, Investigational
AmifostineCilazapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Cilazapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Cilazapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Cilazapril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilazapril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cilazapril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Cilazapril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Cilazapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Cilazapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Cilazapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Cilazapril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilazapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cilazapril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cilazapril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Cilazapril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Cilazapril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Cilazapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Cilazapril.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Cilazapril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Cilazapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Cilazapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cilazapril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cilazapril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Cilazapril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cilazapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Cilazapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Cilazapril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Cilazapril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cilazapril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Cilazapril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Cilazapril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cilazapril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Cilazapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Cilazapril.Illicit
BarnidipineCilazapril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Cilazapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Cilazapril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Cilazapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Cilazapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Cilazapril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cilazapril.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Cilazapril.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Cilazapril.Approved
BepridilBepridil may increase the hypotensive activities of Cilazapril.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Cilazapril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Cilazapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Cilazapril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Cilazapril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Cilazapril.Approved
BoceprevirThe serum concentration of Cilazapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Cilazapril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Cilazapril.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cilazapril.Approved
BQ-123Cilazapril may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cilazapril.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Cilazapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Cilazapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Cilazapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cilazapril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Cilazapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Cilazapril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cilazapril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Cilazapril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Cilazapril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cilazapril.Approved, Investigational
BupranololCilazapril may increase the hypotensive activities of Bupranolol.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Cilazapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Cilazapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Cilazapril.Experimental
CafedrineCilazapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Cilazapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Cilazapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Cilazapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Cilazapril.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Cilazapril.Approved
CarbamazepineThe metabolism of Cilazapril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Cilazapril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Cilazapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Cilazapril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Cilazapril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Cilazapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Cilazapril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cilazapril.Approved, Investigational
CeliprololCilazapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Cilazapril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Cilazapril.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cilazapril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Cilazapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cilazapril.Approved
CicletanineCilazapril may increase the hypotensive activities of Cicletanine.Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Cilazapril.Approved, Investigational
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Cilazapril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilazapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Cilazapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Cilazapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Cilazapril.Approved
CloranololCilazapril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cilazapril.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cilazapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Cilazapril.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Cilazapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Cilazapril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Cilazapril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Cilazapril.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Cilazapril.Approved, Investigational
DelaprilCilazapril may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Cilazapril.Approved
DersalazineThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineCilazapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cilazapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Cilazapril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cilazapril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Cilazapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Cilazapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Cilazapril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Cilazapril.Approved, Investigational
DiethylnorspermineCilazapril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cilazapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Cilazapril.Experimental
DiflunisalThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cilazapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Cilazapril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilazapril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Cilazapril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Cilazapril.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Cilazapril.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Cilazapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Cilazapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Cilazapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Cilazapril.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cilazapril.Approved, Investigational
DrospirenoneCilazapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Cilazapril.Withdrawn
DuloxetineCilazapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cilazapril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Cilazapril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Cilazapril.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cilazapril.Approved
EfonidipineCilazapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
EnalaprilatCilazapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Cilazapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Cilazapril.Approved, Investigational
EpanololCilazapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Cilazapril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Cilazapril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Cilazapril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Cilazapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Cilazapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Cilazapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Cilazapril.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Cilazapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Cilazapril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cilazapril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Cilazapril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cilazapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Cilazapril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Cilazapril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cilazapril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Cilazapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Cilazapril.Investigational, Nutraceutical
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cilazapril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Cilazapril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Cilazapril.Experimental
FelodipineFelodipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Cilazapril.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Cilazapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Cilazapril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cilazapril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Cilazapril.Experimental
Ferulic acidCilazapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Cilazapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Cilazapril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Cilazapril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Cilazapril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Cilazapril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Cilazapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Cilazapril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Cilazapril.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Cilazapril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
GarlicThe serum concentration of Cilazapril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GuacetisalThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Cilazapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Cilazapril.Approved
GuanazodineCilazapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Cilazapril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Cilazapril.Approved, Investigational
GuanoclorCilazapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCilazapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCilazapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Cilazapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Cilazapril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Cilazapril is combined with Heparin.Approved, Investigational
HexamethoniumCilazapril may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Cilazapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Cilazapril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Cilazapril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Cilazapril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Cilazapril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Cilazapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Cilazapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Cilazapril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Cilazapril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Cilazapril.Approved, Investigational
ImidaprilCilazapril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Cilazapril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cilazapril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Cilazapril.Approved
IndenololCilazapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Cilazapril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cilazapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cilazapril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Cilazapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Cilazapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Cilazapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Cilazapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Cilazapril.Approved, Investigational
IronIron can cause a decrease in the absorption of Cilazapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cilazapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cilazapril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilazapril.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Cilazapril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cilazapril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Cilazapril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Cilazapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Cilazapril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Cilazapril.Approved
LabetalolLabetalol may increase the hypotensive activities of Cilazapril.Approved
LacidipineCilazapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Cilazapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cilazapril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Cilazapril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cilazapril.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Cilazapril.Approved, Investigational
LevodopaCilazapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Cilazapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Cilazapril.Approved
LinsidomineCilazapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Cilazapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cilazapril.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Cilazapril.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Cilazapril.Experimental
LofexidineCilazapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Cilazapril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cilazapril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Cilazapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cilazapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cilazapril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Cilazapril.Approved, Investigational
MacitentanCilazapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cilazapril.Approved
ManidipineCilazapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Cilazapril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Cilazapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Cilazapril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cilazapril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Cilazapril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Cilazapril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Cilazapril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Cilazapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cilazapril.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Cilazapril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Cilazapril.Approved
MethoserpidineCilazapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Cilazapril.Approved
Methyl salicylateThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Cilazapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Cilazapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Cilazapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cilazapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Cilazapril.Approved
MetipranololMetipranolol may increase the hypotensive activities of Cilazapril.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Cilazapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Cilazapril.Approved, Investigational
MetyrosineCilazapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilCilazapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cilazapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Cilazapril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Cilazapril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Cilazapril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cilazapril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Cilazapril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Cilazapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Cilazapril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Cilazapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cilazapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Cilazapril.Approved, Investigational
MuzolimineCilazapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cilazapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cilazapril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Cilazapril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cilazapril.Approved
NadololNadolol may increase the hypotensive activities of Cilazapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cilazapril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Cilazapril.Approved
NaftopidilCilazapril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cilazapril.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Cilazapril.Approved, Vet Approved
NebivololCilazapril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Cilazapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Cilazapril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Cilazapril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Cilazapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilazapril.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Cilazapril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Cilazapril.Approved
NiguldipineCilazapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineCilazapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cilazapril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Cilazapril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Cilazapril.Approved
NitroaspirinThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Cilazapril.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Cilazapril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Cilazapril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Cilazapril.Approved
ObinutuzumabCilazapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Cilazapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Cilazapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cilazapril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cilazapril.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Cilazapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Cilazapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Cilazapril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cilazapril.Approved
OxprenololCilazapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cilazapril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cilazapril.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cilazapril.Experimental, Nutraceutical
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Cilazapril.Approved
PargylinePargyline may increase the hypotensive activities of Cilazapril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Cilazapril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cilazapril.Approved
PenbutololCilazapril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Cilazapril.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Cilazapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cilazapril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Cilazapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Cilazapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Cilazapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Cilazapril.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Cilazapril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cilazapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Cilazapril.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cilazapril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cilazapril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Cilazapril.Approved
PindololPindolol may increase the hypotensive activities of Cilazapril.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cilazapril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Cilazapril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Cilazapril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Cilazapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cilazapril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Cilazapril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Cilazapril.Withdrawn
Platelet Activating FactorCilazapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Cilazapril.Approved
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Cilazapril.Approved
Potassium cationPotassium may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Cilazapril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Cilazapril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Cilazapril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Cilazapril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Cilazapril.Approved
PregabalinThe risk or severity of angioedema can be increased when Cilazapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Cilazapril.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Cilazapril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Cilazapril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cilazapril.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cilazapril.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Cilazapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Cilazapril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Cilazapril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Cilazapril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cilazapril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Cilazapril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.Approved
QuinaprilQuinapril may increase the hypotensive activities of Cilazapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Cilazapril.Approved
QuinineQuinine may increase the hypotensive activities of Cilazapril.Approved
RamiprilRamipril may increase the hypotensive activities of Cilazapril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cilazapril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Cilazapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cilazapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Cilazapril.Approved
RescinnamineCilazapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Cilazapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cilazapril.Approved, Experimental, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cilazapril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Cilazapril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Cilazapril.Approved
RisperidoneCilazapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabCilazapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Cilazapril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Cilazapril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cilazapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Cilazapril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Cilazapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Cilazapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Cilazapril.Approved
Salicylic acidThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Cilazapril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Cilazapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Cilazapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Cilazapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Cilazapril.Approved, Investigational, Vet Approved
SelexipagCilazapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Cilazapril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cilazapril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cilazapril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cilazapril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Cilazapril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cilazapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cilazapril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Cilazapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Cilazapril.Approved, Investigational
SitaxentanCilazapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Cilazapril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphate, monobasicCilazapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.Approved
SpiraprilCilazapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Cilazapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Cilazapril.Investigational
St. John's WortThe metabolism of Cilazapril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Cilazapril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cilazapril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cilazapril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Cilazapril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Cilazapril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Cilazapril.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cilazapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Cilazapril.Approved, Investigational
TalinololCilazapril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Cilazapril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cilazapril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Cilazapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Cilazapril.Approved, Investigational
TemocaprilCilazapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Cilazapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Cilazapril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Cilazapril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Cilazapril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Cilazapril.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Cilazapril.Approved
TerlipressinCilazapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineCilazapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cilazapril.Approved, Investigational, Withdrawn
TheodrenalineCilazapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Cilazapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cilazapril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Cilazapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cilazapril.Approved
TiboloneCilazapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenCilazapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Cilazapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Cilazapril.Investigational
TipranavirThe serum concentration of Cilazapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Cilazapril.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cilazapril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cilazapril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cilazapril.Approved
TolonidineCilazapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Cilazapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Cilazapril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cilazapril.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Cilazapril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Cilazapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Cilazapril.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Cilazapril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Cilazapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Cilazapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Cilazapril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Cilazapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Cilazapril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Cilazapril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Cilazapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Cilazapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Cilazapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Cilazapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Cilazapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Cilazapril.Investigational
Trolamine salicylateThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Cilazapril.Approved, Investigational
UnoprostoneCilazapril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Cilazapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cilazapril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Cilazapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Cilazapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Cilazapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Cilazapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cilazapril.Approved, Investigational
VincamineCilazapril may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Cilazapril.Approved, Investigational
VinpocetineCilazapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideCilazapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineCilazapril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Cilazapril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cilazapril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Cilazapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Cilazapril.Approved, Investigational, Withdrawn
ZofenoprilCilazapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cilazapril.Withdrawn
Food Interactions
  • Food decreases cilazapril absorption with no significant clinical impact.
  • Take without regard to meals.

References

Synthesis Reference

Attwood, M. R.; Hassall, C. H.; Kr�Hn, A.; Lawton, G.; Redshaw, S. (1986). "The design and synthesis of the Angiotensin Converting Enzyme inhibitor Cilazapril and related bicyclic compounds". Journal of the Chemical Society, Perkin Transactions 1: 1011. doi:10.1039/P19860001011

US20060293517
General References
  1. Fasanella d'Amore T, Bussien JP, Nussberger J, Waeber B, Turini GA, Brunner HR, Kler L, Francis RJ: Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol. 1987 Jan;9(1):26-31. [PubMed:2434790]
External Links
Human Metabolome Database
HMDB0015433
KEGG Drug
D07699
PubChem Compound
56330
PubChem Substance
46505231
ChemSpider
50831
ChEBI
3698
ChEMBL
CHEMBL515606
Therapeutic Targets Database
DAP000912
PharmGKB
PA164748302
Drugs.com
Drugs.com Drug Page
Wikipedia
Cilazapril
ATC Codes
C09BA08 — Cilazapril and diureticsC09AA08 — Cilazapril
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (114 KB)
MSDS
Download (81.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusTreatmentIgA Glomerulonephritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral
TabletOral1 mg
TabletOral1.0 mg
TabletOral2.5 mg
TabletOral5.0 mg
Prices
Unit descriptionCostUnit
Inhibace 5 mg Tablet0.94USD tablet
Inhibace 2.5 mg Tablet0.81USD tablet
Inhibace 1 mg Tablet0.7USD tablet
Apo-Cilazapril 5 mg Tablet0.52USD tablet
Co Cilazapril 5 mg Tablet0.52USD tablet
Mylan-Cilazapril 5 mg Tablet0.52USD tablet
Novo-Cilazapril 5 mg Tablet0.52USD tablet
Pms-Cilazapril 5 mg Tablet0.52USD tablet
Apo-Cilazapril 2.5 mg Tablet0.45USD tablet
Co Cilazapril 2.5 mg Tablet0.45USD tablet
Mylan-Cilazapril 2.5 mg Tablet0.45USD tablet
Novo-Cilazapril 2.5 mg Tablet0.45USD tablet
Pms-Cilazapril 2.5 mg Tablet0.45USD tablet
Apo-Cilazapril 1 mg Tablet0.39USD tablet
Mylan-Cilazapril 1 mg Tablet0.39USD tablet
Novo-Cilazapril 1 mg Tablet0.39USD tablet
Pms-Cilazapril 1 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20060293517No2004-03-082024-03-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)98 ºC with decomposition Not Available
water solubilityWater (25 ºC) 0.5 g/100 mL Not Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.06 mg/mLALOGPS
logP-0.2ALOGPS
logP-0.0079ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)5.35ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity110.56 m3·mol-1ChemAxon
Polarizability44.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier-0.9402
Caco-2 permeable-0.7698
P-glycoprotein substrateSubstrate0.8727
P-glycoprotein inhibitor IInhibitor0.7775
P-glycoprotein inhibitor IINon-inhibitor0.8788
Renal organic cation transporterNon-inhibitor0.8318
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.8283
CYP450 3A4 substrateSubstrate0.5396
CYP450 1A2 substrateNon-inhibitor0.882
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.7503
CYP450 2C19 inhibitorNon-inhibitor0.816
CYP450 3A4 inhibitorNon-inhibitor0.8201
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8376
Ames testNon AMES toxic0.6023
CarcinogenicityNon-carcinogens0.9028
BiodegradationNot ready biodegradable0.9942
Rat acute toxicity2.3700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9311
hERG inhibition (predictor II)Inhibitor0.6303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / 1,2-diazepanes / Fatty acid esters / Aralkylamines / Pyridazines and derivatives / Dicarboxylic acids and derivatives / Diazinanes / Benzene and substituted derivatives / Amino acids / Carboxylic acid hydrazides
show 8 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / Alpha-amino acid or derivatives / 1,2-diazepane / Fatty acid ester / Diazepane / Aralkylamine / Dicarboxylic acid or derivatives / 1,2-diazinane / Pyridazine
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, Yoshikawa J: Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension. 1999 Apr;33(4):961-8. [PubMed:10205231]
  2. Kihara M, Mitsui MK, Mitsui Y, Okuda K, Nakasaka Y, Takahashi M, Schmelzer JD: Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve. 1999 Jul;22(7):920-5. [PubMed:10398211]
  3. Mervaala E, Dehmel B, Gross V, Lippoldt A, Bohlender J, Milia AF, Ganten D, Luft FC: Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol. 1999 Aug;10(8):1669-80. [PubMed:10446934]
  4. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157]
  5. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161]
  6. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18. [PubMed:18423812]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 30, 2007 12:09 / Updated on July 13, 2018 01:08